An Update on the Benefits and Safety Profile of Hydroxychloroquine

Authors

  • Mais M. Nuaaman, MD, MSc Division of Rheumatology, St. Joseph’s Health Care, London, ON Department of Medicine, Schulich School of Medicine & Dentistry, University of Western Ontario, London, ON

DOI:

https://doi.org/10.58931/crt.2024.1356

Abstract

Hydroxychloroquine, an antimalarial drug developed in 1950, has been used for decades in the management of various systemic autoimmune rheumatic diseases. By targeting both the innate and adaptive immune systems, it exerts widespread immunomodulatory effects to attenuate the inflammatory response and exert antirheumatic effects. Its favourable safety profile, coupled with proven benefits in improving disease activity and decreasing morbidity and mortality, especially in patients with systemic lupus erythematosus and rheumatoid arthritis, has solidified its place in the long-term management of patients with rheumatic diseases. Recently, therapeutic drug level monitoring has been used to predict the risks of disease flares and prevent treatment-related toxicity. This review article briefly reviews the benefits of using hydroxychloroquine in the management of systemic autoimmune rheumatic diseases, its common and serious adverse effect profile, and the role of drug blood level monitoring in improving patient-related health outcomes.

Author Biography

Mais M. Nuaaman, MD, MSc, Division of Rheumatology, St. Joseph’s Health Care, London, ON Department of Medicine, Schulich School of Medicine & Dentistry, University of Western Ontario, London, ON

Dr. Mais Nuaaman is a Rheumatology resident at Western University in London, Ontario, Canada. She graduated with an honours degree in Biochemistry from York University in Toronto, Ontario where she then went on to complete a Masters of Science in Biology. She then moved to Newfoundland and Labrador for undergraduate medical training, earning the Doctor of Medicine degree at Memorial University. She moved back to Ontario for residency training in Internal Medicine and Rheumatology. Her interests lie in complex connective tissue diseases and in systemic vasculitides.

References

DRUGS@FDA: FDA-approved drugs [Internet]. U.S. Food and Drug Administration.; [cited 2024 Nov 24]. Available from: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=009768

Fanouriakis A, Kostopoulou M, Andersen J, Aringer M, Arnaud L, Bae SC, et al. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis. 2024;83(1):15-29. doi: 10.1136/ard-2023-224762. DOI: https://doi.org/10.1136/ard-2024-225617

Sammaritano LR, Bermas BL, Chakravarty EE, Chambers C, Clowse MEB, Lockshin MD, et al. 2020 American College of Rheumatology Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases. Arthritis Care Res (Hoboken). 2020;72(4):461-488. doi: 10.1002/acr.24130. DOI: https://doi.org/10.1002/acr.24130

Andreoli L, Bertsias GK, Agmon-Levin N, Brown S, Cervera R, Costedoat-Chalumeau N, et al. EULAR recommendations for women’s health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome. Ann Rheum Dis. 2017;76(3):476-485. doi: 10.1136/annrheumdis-2016-209770. DOI: https://doi.org/10.1136/annrheumdis-2016-209770

Smolen JS, Landewé RBM, Bergstra SA, Kerschbaumer A, Sepriano A, Aletaha D, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3-18. doi: 10.1136/ard-2022-223356. Erratum in: Ann Rheum Dis. 2023;82(3):e76. doi: 10.1136/ard-2022-223356corr1. DOI: https://doi.org/10.1136/ard-2022-223356corr1

Fraenkel L, Bathon JM, England BR, St Clair EW, Arayssi T, Carandang K, et al. 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Rheumatol. 2021;73(7):1108-1123. doi: 10.1002/art.41752. DOI: https://doi.org/10.1002/art.41752

Tektonidou MG, Andreoli L, Limper M, Amoura Z, Cervera R, Costedoat-Chalumeau N, et al. EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis. 2019;78(10):1296-1304. doi: 10.1136/annrheumdis-2019-215213. DOI: https://doi.org/10.1136/annrheumdis-2019-215213

Hooper A, Bacal V, Bedaiwy MA. Does adding hydroxychloroquine to empiric treatment improve the live birth rate in refractory obstetrical antiphospholipid syndrome? A systematic review. Am J Reprod Immunol. 2023;90(3):e13761. doi: 10.1111/aji.13761. DOI: https://doi.org/10.1111/aji.13761

Gerde M, Ibarra E, Mac Kenzie R, Fernandez Suarez C, Heer C, Alvarez R, et al. The impact of hydroxychloroquine on obstetric outcomes in refractory obstetric antiphospholipid syndrome. Thromb Res. 2021;206:104-110. doi: 10.1016/j.thromres.2021.08.004. DOI: https://doi.org/10.1016/j.thromres.2021.08.004

Izmirly P, Kim M, Friedman DM, Costedoat-Chalumeau N, Clancy R, Copel JA, et al. Hydroxychloroquine to prevent recurrent congenital heart block in fetuses of Anti-SSA/Ro-Positive mothers. J Am Coll Cardiol. 2020;76(3):292-302. doi: 10.1016/j.jacc.2020.05.045. DOI: https://doi.org/10.1016/j.jacc.2020.05.045

Study of Anti-Malarials in Incomplete Lupus Erythematosus (SMILE) [Internet]. Clinicaltrials.gov; [cited 2024 Dec 7]. Available from: https://clinicaltrials.gov/study/NCT03030118?term=NCT03030118.&rank=1

Schrezenmeier E, Dörner T. Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol. 2020;16(3):155-166. doi: 10.1038/s41584-020-0372-x. DOI: https://doi.org/10.1038/s41584-020-0372-x

Gisondi P, Piaserico S, Bordin C, Bellinato F, Tozzi F, Alaibac M, et al. The safety profile of hydroxychloroquine: major cutaneous and extracutaneous adverse events. Clin Exp Rheumatol. 2021;39(5):1099-1107. doi: 10.55563/clinexprheumatol/styx9u. DOI: https://doi.org/10.55563/clinexprheumatol/styx9u

Canadian Hydroxychloroquine Study Group. A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. N Engl J Med. 1991;324(3):150-154. doi: 10.1056/NEJM199101173240303. DOI: https://doi.org/10.1056/NEJM199101173240303

Bruce IN, O’Keeffe AG, Farewell V, Hanly JG, Manzi S, Su L, et al. Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. Ann Rheum Dis. 2015;74(9):1706-1713. doi: 10.1136/annrheumdis-2013-205171. DOI: https://doi.org/10.1136/annrheumdis-2013-205171

Akhavan PS, Su J, Lou W, Gladman DD, Urowitz MB, Fortin PR. The early protective effect of hydroxychloroquine on the risk of cumulative damage in patients with systemic lupus erythematosus. J Rheumatol. 2013;40(6):831-841. doi: 10.3899/jrheum.120572. DOI: https://doi.org/10.3899/jrheum.120572

Pakchotanon R, Gladman DD, Su J, Urowitz MB. More consistent antimalarial intake in first 5 years of disease is associated with better prognosis in patients with systemic lupus erythematosus. J Rheumatol. 2018;45(1):90-94. doi: 10.3899/jrheum.170645. Erratum in: J Rheumatol. 2019;46(11):1548. doi: 10.3899/jrheum.170645.C1. PMID: 29142038. DOI: https://doi.org/10.3899/jrheum.170645

Jin Z, Wang F, Pan W, Liu L, Wu M, Hu H, et al. Association of antimalarial drugs with decreased overall and cause specific mortality in systemic lupus erythematosus. Rheumatology (Oxford). 2021;60(4):1774-1783. doi: 10.1093/rheumatology/keaa485. DOI: https://doi.org/10.1093/rheumatology/keaa485

Alarcón GS, McGwin G, Bertoli AM, Fessler BJ, Calvo-Alén J, Bastian HM, et al. Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L). Ann Rheum Dis. 2007;66(9):1168-1172. doi: 10.1136/ard.2006.068676. DOI: https://doi.org/10.1136/ard.2006.068676

Ruiz-Irastorza G, Martín-Iglesias D, Soto-Peleteiro A. Update on antimalarials and systemic lupus erythematosus. Curr Opin Rheumatol. 2020;32(6):572-582. doi: 10.1097/BOR.0000000000000743. DOI: https://doi.org/10.1097/BOR.0000000000000743

Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, Khamashta MA. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis. 2010;69(1):20-28. doi: 10.1136/ard.2008.101766. DOI: https://doi.org/10.1136/ard.2008.101766

Suarez-Almazor ME, Belseck E, Shea B, Homik J, Wells G, Tugwell P. Antimalarials for treating rheumatoid arthritis. Cochrane Database Syst Rev. 2000;(4):CD000959. doi: 10.1002/14651858.CD000959. DOI: https://doi.org/10.1002/14651858.CD000959

Klarenbeek NB, Güler-Yüksel M, van der Kooij SM, Han KH, Ronday HK, Kerstens PJ, et al. The impact of four dynamic, goal-steered treatment strategies on the 5-year outcomes of rheumatoid arthritis patients in the BeSt study. Ann Rheum Dis. 2011;70(6):1039-1046. doi: 10.1136/ard.2010.141234. DOI: https://doi.org/10.1136/ard.2010.141234

Rempenault C, Combe B, Barnetche T, Gaujoux-Viala C, Lukas C, Morel J, et al. Metabolic and cardiovascular benefits of hydroxychloroquine in patients with rheumatoid arthritis: a systematic review and meta-analysis. Ann Rheum Dis. 2018;77(1):98-103. doi: 10.1136/annrheumdis-2017-211836. DOI: https://doi.org/10.1136/annrheumdis-2017-211836

Chen YM, Lin CH, Lan TH, Chen HH, Chang SN, Chen YH, et al. Hydroxychloroquine reduces risk of incident diabetes mellitus in lupus patients in a dose-dependent manner: a population-based cohort study. Rheumatology (Oxford). 2015;54(7):1244-1249. doi: 10.1093/rheumatology/keu451. DOI: https://doi.org/10.1093/rheumatology/keu451

Wasko MC, Hubert HB, Lingala VB, Elliott JR, Luggen ME, Fries JF, et al. Hydroxychloroquine and risk of diabetes in patients with rheumatoid arthritis. JAMA. 2007;298(2):187-193. doi: 10.1001/jama.298.2.187. DOI: https://doi.org/10.1001/jama.298.2.187

Babary H, Liu X, Ayatollahi Y, Chen XP, Doo L, Uppaluru LK, et al. Favorable effects of hydroxychloroquine on serum low density lipid in patients with systemic lupus erythematosus: a systematic review and meta-analysis. Int J Rheum Dis. 2018;21(1):84-92. doi: 10.1111/1756-185X.13159. DOI: https://doi.org/10.1111/1756-185X.13159

Kavanaugh A, Adams-Huet B, Jain R, Denke M, McFarlin J. Hydroxychloroquine effects on lipoprotein profiles (the HELP trial): a double-blind, randomized, placebo-controlled, pilot study in patients with systemic lupus erythematosus. J Clin Rheumatol. 1997;3(1):3-8. DOI: https://doi.org/10.1097/00124743-199702000-00002

Stojan G, Petri M. Atherosclerosis in systemic lupus erythematosus. J Cardiovasc Pharmacol. 2013;62(3):255-262. doi: 10.1097/FJC.0b013e31829dd857. DOI: https://doi.org/10.1097/FJC.0b013e31829dd857

Petri M, Konig MF, Li J, Goldman DW. Association of higher hydroxychloroquine blood levels with reduced thrombosis risk in systemic lupus erythematosus. arthritis Rheumatol. 2021;73(6):997-1004. doi: 10.1002/art.41621. DOI: https://doi.org/10.1002/art.41621

Fairley JL, Nikpour M, Mack HG, Brosnan M, Saracino AM, Pellegrini M, et al. How toxic is an old friend? A review of the safety of hydroxychloroquine in clinical practice. Intern Med J. 2023;53(3):311-317. doi: 10.1111/imj.15908. DOI: https://doi.org/10.1111/imj.15908

Mates M, Zevin S, Breuer GS, Navon P, Nesher G. Desensitization to hydroxychloroquine--experience of 4 patients. J Rheumatol. 2006 Apr;33(4):814-6. Epub 2006 Feb 1. PMID: 16463436.

Tal Y, Maoz Segal R, Langevitz P, Kivity S, Darnizki Z, Agmon-Levin N. Hydroxychloroquine desensitization, an effective method to overcome hypersensitivity-a multicenter experience. Lupus. 2018 Apr;27(5):703-707. doi: 10.1177/0961203317735185. Epub 2017 Oct 9. PMID: 28992797. DOI: https://doi.org/10.1177/0961203317735185

Sharma AN, Mesinkovska NA, Paravar T. Characterizing the adverse dermatologic effects of hydroxychloroquine: a systematic review. J Am Acad Dermatol. 2020;83(2):563-578. doi: 10.1016/j.jaad.2020.04.024. DOI: https://doi.org/10.1016/j.jaad.2020.04.024

Makin AJ, Wendon J, Fitt S, Portmann BC, Williams R. Fulminant hepatic failure secondary to hydroxychloroquine. Gut. 1994;35(4):569-570. doi: 10.1136/gut.35.4.569. DOI: https://doi.org/10.1136/gut.35.4.569

Abdel Galil SM. Hydroxychloroquine-induced toxic hepatitis in a patient with systemic lupus erythematosus: a case report. Lupus. 2015;24(6):638-640. doi: 10.1177/0961203314561667. DOI: https://doi.org/10.1177/0961203314561667

Tselios K, Deeb M, Gladman DD, Harvey P, Akhtari S, Mak S, et al. Antimalarial-induced cardiomyopathy in systemic lupus erythematosus: as rare as considered? J Rheumatol. 2019;46(4):391-396. doi: 10.3899/jrheum.180124. DOI: https://doi.org/10.3899/jrheum.180124

Marmor MF, Kellner U, Lai TY, Melles RB, Mieler WF; American Academy of Ophthalmology. Recommendations on Screening for chloroquine and hydroxychloroquine retinopathy (2016 Revision). Ophthalmology. 2016;123(6):1386-1394. doi: 10.1016/j.ophtha.2016.01.058. DOI: https://doi.org/10.1016/j.ophtha.2016.01.058

Petri M, Elkhalifa M, Li J, Magder LS, Goldman DW. Hydroxychloroquine blood levels predict hydroxychloroquine retinopathy. Arthritis Rheumatol. 2020;72(3):448-453. doi: 10.1002/art.41121. Epub 2020 Jan 7. DOI: https://doi.org/10.1002/art.41121

Lenfant T, Salah S, Leroux G, Bousquet E, Le Guern V, Chasset F, et al. Risk factors for hydroxychloroquine retinopathy in systemic lupus erythematosus: a case-control study with hydroxychloroquine blood-level analysis. Rheumatology (Oxford). 2020;59(12):3807-3816. doi: 10.1093/rheumatology/keaa157. DOI: https://doi.org/10.1093/rheumatology/keaa157

Bansal P, Goyal A, Cusick A 4th, Lahan S, Dhaliwal HS, Bhyan P, et al. Hydroxychloroquine: a comprehensive review and its controversial role in coronavirus disease 2019. Ann Med. 2021 Dec;53(1):117-134. doi: 10.1080/07853890.2020.1839959.. DOI: https://doi.org/10.1080/07853890.2020.1839959

Talarico F, Chakravarty S, Liu YS, Greenshaw AJ, Passos IC, Cao B. Systematic review of psychiatric adverse effects induced by chloroquine and hydroxychloroquine: case reports and population studies. Ann Pharmacother. 2023;57(4):463-479. doi: 10.1177/10600280221113572. DOI: https://doi.org/10.1177/10600280221113572

Biguetti CC, Junior JFS, Fiedler MW, Marrelli MT, Brotto M. The toxic effects of chloroquine and hydroxychloroquine on skeletal muscle: a systematic review and meta-analysis. Sci Rep. 2021;11(1):6589. doi: 10.1038/s41598-021-86079-4. DOI: https://doi.org/10.1038/s41598-021-86079-4

Garg S, Unnithan R, Hansen KE, Costedoat-Chalumeau N, Bartels CM. Clinical significance of monitoring hydroxychloroquine levels in patients with systemic lupus erythematosus: a systematic review and meta-analysis. Arthritis Care Res (Hoboken). 2021;73(5):707-716. doi: 10.1002/acr.24155. DOI: https://doi.org/10.1002/acr.24155

Garg S, Chewning B, Hutson P, Astor BC, Bartels CM. Reference range of hydroxychloroquine blood levels that can reduce odds of active lupus and prevent flares. Arthritis Care Res (Hoboken). 2024;76(2):241-250. doi: 10.1002/acr.25228. DOI: https://doi.org/10.1002/acr.25228

Garg S, Astor BC, Saric C, Valiente G, Kolton L, Chewning B, et al. Therapeutic hydroxychloroquine blood levels are associated with fewer hospitalizations and possible reduction of health disparities in lupus. Arthritis Care Res (Hoboken). Published online August 26, 2024. doi: 10.1002/acr.25422. DOI: https://doi.org/10.1002/acr.25422

Fasano S, Messiniti V, Iudici M, Coscia MA, Ciccia F. Hydroxychloroquine daily dose, hydroxychloroquine blood levels and the risk of flares in patients with systemic lupus erythematosus. Lupus Sci Med. 2023;10(1):e000841. doi: 10.1136/lupus-2022-000841. DOI: https://doi.org/10.1136/lupus-2022-000841

Nguyen Y, Blanchet B, Urowitz MB, Hanly JG, Gordon C, Bae SC, et al. Association between severe nonadherence to hydroxychloroquine and systemic lupus erythematosus flares, damage, and mortality in 660 patients from the SLICC Inception cohort. Arthritis Rheumatol. 2023 ;75(12):2195-2206. doi: 10.1002/art.42645 DOI: https://doi.org/10.1002/art.42645

Jallouli M, Francès C, Piette JC, Huong du LT, Moguelet P, Factor C, et al. Hydroxychloroquine-induced pigmentation in patients with systemic lupus erythematosus: a case-control study. JAMA Dermatol. 2013;149(8):935-940. doi: 10.1001/jamadermatol.2013.709. DOI: https://doi.org/10.1001/jamadermatol.2013.709

Munster T, Gibbs JP, Shen D, Baethge BA, Botstein GR, Caldwell J, et al. Hydroxychloroquine concentration-response relationships in patients with rheumatoid arthritis. Arthritis Rheum. 2002 ;46(6):1460-1469. doi: 10.1002/art.10307. DOI: https://doi.org/10.1002/art.10307

Damstetter E, Vashi N. Treatment of hydroxychloroquine-induced hyperpigmentation of the lower extremities with the Q-switched 755-nm Alexandrite Laser. Journal of the American Academy of Dermatology. 2017 Jun;76(6):AB266. doi:10.1016/j.jaad.2017.04.1031 DOI: https://doi.org/10.1016/j.jaad.2017.04.1031

Desmarais J, Rosenbaum JT, Costenbader KH, Ginzler EM, Fett N, Goodman S, O’Dell J, Pineau CA, Schmajuk G, Werth VP, Link MS, Kovacs R. American College of Rheumatology White Paper on Antimalarial Cardiac Toxicity. Arthritis Rheumatol. 2021 Dec;73(12):2151-2160. doi: 10.1002/art.41934. Epub 2021 Oct 26. PMID: 34697918. DOI: https://doi.org/10.1002/art.41934

McGhie TK, Harvey P, Su J, Anderson N, Tomlinson G, Touma Z. Electrocardiogram abnormalities related to anti-malarials in systemic lupus erythematosus. Clin Exp Rheumatol. 2018 Jul-Aug;36(4):545-551. Epub 2018 Apr 13. PMID: 29652656.

Canadian Rheumatology Association position statement ... [Internet]. Canadian Rheumatology Association; 2021 [cited 2024 Dec 13]. Available from: https://rheum.ca/wp-content/uploads/2021/01/FINAL-ENGLISH-Canadian-Rheumatology-Association-Position-Statement-on-the-Safety-of-Hydroxychloroqine.pdf

Rosenbaum JT, Costenbader KH, Desmarais J, Ginzler EM, Fett N, Goodman SM, O’Dell JR, Schmajuk G, Werth VP, Melles RB, Marmor MF. American College of Rheumatology, American Academy of Dermatology, Rheumatologic Dermatology Society, and American Academy of Ophthalmology 2020 Joint Statement on Hydroxychloroquine Use With Respect to Retinal Toxicity. Arthritis Rheumatol. 2021 Jun;73(6):908-911. doi: 10.1002/art.41683. Epub 2021 Apr 26. PMID: 33559327. DOI: https://doi.org/10.1002/art.41683

Hydroxychloroquine in human whole blood or serum [Internet]. Dynacare; [cited 2024 Dec 13]. Available from: https://www.dynacare.ca/specialpages/secondarynav/find-a-test/nat/

Hydroxychloroquine, whole blood [Internet]. Labcorp; [cited 2024 Dec 13]. Available from: https://www.labcorp.com/tests/504814/hydroxychloroquine-whole blood

Downloads

Published

2024-12-18

How to Cite

1.
Nuaaman MM. An Update on the Benefits and Safety Profile of Hydroxychloroquine. Can Rheumatol Today [Internet]. 2024 Dec. 18 [cited 2025 Jan. 22];1(3):26–34. Available from: https://canadianrheumatologytoday.com/article/view/1-3-Nuaaman

Issue

Volume 1, Issue 3, Fall 2024

Section

Articles

License

Copyright (c) 2024 Canadian Rheumatology Today

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.